Ambience Healthcare vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ambience Healthcare raised $370M (~$1B valuation) and hit $30M ARR with ambient AI documentation across 100+ specialties, eliminating the documentation burden driving clinician burnout.
About
Ambience Healthcare was founded in 2020 in San Francisco with a mission to eliminate the documentation burden that drives clinician burnout and degrades patient care quality across health systems. The company builds ambient AI documentation technology that listens to clinical encounters across more than 100 medical and surgical specialties, generating accurate, complete clinical notes in the background without requiring clinicians to dictate or type. Ambience's core technology leverages large language models purpose-trained on clinical language, specialty-specific note structures, and electronic health record formatting requirements to produce documentation that is ready for review with minimal editing.\n\nAmbience's platform is deployed across health systems ranging from large academic medical centers to independent practices, covering more than 100 specialties including primary care, surgery, oncology, behavioral health, and pediatrics. Unlike narrower documentation tools that focus on a single specialty or encounter type, Ambience's breadth allows health systems to deploy a single solution enterprise-wide. The platform integrates with major EHR systems including Epic and Cerner, embedding documentation into existing clinical workflows without requiring behavior change from clinicians. Ambience achieved approximately $30 million in annual recurring revenue as of May 2025.\n\nAmbience Healthcare has raised approximately $370 million in total funding, approaching a $1 billion valuation, from investors including Andreessen Horowitz and other leading healthcare-focused venture firms. The company competes with Nuance DAX, Suki, and Nabla in the ambient documentation space but differentiates through its specialty breadth, enterprise EHR integration depth, and strong health system relationships. As health systems face escalating clinician burnout and documentation-driven inefficiency, Ambience's full-enterprise approach positions it as a platform of record for ambient clinical intelligence.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.